What ECG findings are expected after atrial septal defect (ASD) closure and what is the recommended ECG monitoring schedule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ECG Monitoring After Atrial Septal Defect Closure

For asymptomatic patients after device closure of ASD, obtain ECG surveillance at 1 week, 1 month, 3-6 months, and 1 year post-procedure, then every 2-5 years thereafter; for surgical closure, obtain ECG within the first year, then consider every 2-5 years if no complications develop. 1

Expected ECG Findings After ASD Closure

Immediate Post-Closure Changes (Within Days to Weeks)

  • QRS axis normalization: Mean axis decreases from approximately 108° to 70° 2
  • QRS duration reduction: Mean duration decreases from 123 ms to 80 ms 2
  • PR interval shortening: Mean PR interval reduces from 188 ms to 123 ms 2
  • Crochetage sign disappearance in patients who had it pre-closure 2

Progressive Changes (Months to 1 Year)

  • Right bundle branch block pattern evolution: The amplitude of R' wave in rSR' pattern in right precordial leads progressively reduces 2
  • Pattern reversion: rR' and qR patterns in right precordial leads typically revert to rSr' pattern in most patients (83% in one study) 2
  • P-wave changes: Maximal P-wave duration may initially increase (75 ms to 81 ms) despite volumetric unloading, possibly due to device "foreign body" effect 3
  • P-wave dispersion: Tends to decrease from approximately 32 ms to 28 ms by 6 months 3

Recommended ECG Monitoring Schedule

Device Closure (Percutaneous)

Asymptomatic patients with no/mild sequelae:

  • Within 1 week: Appropriate 1
  • At 1 month: Appropriate 1
  • At 3-6 months: Appropriate 1
  • At 1 year: Appropriate 1
  • After first year (2-5 year intervals): Appropriate 1

The 2008 ACC/AHA guidelines specify typical echocardiographic follow-up at 24 hours, 1 month, 6 months, and 1 year, with ECG surveillance being an important component 4.

Surgical Closure

Asymptomatic patients with no/mild sequelae:

  • Within first year: Appropriate 1
  • After first year (2-5 year intervals): Appropriate 1
  • Annual surveillance: May be appropriate (rated as "M" in guidelines) 1

Patients with Complications

For patients with residual shunt, valvular/ventricular dysfunction, arrhythmias, or pulmonary hypertension:

  • Every 3-12 months: Appropriate for ongoing surveillance 1
  • Annual follow-up is mandatory if ASD was repaired as an adult and any of these conditions persist: pulmonary arterial hypertension, atrial arrhythmias, RV or LV dysfunction, or coexisting valvular lesions 4, 5, 4

Critical ECG Findings Requiring Urgent Evaluation

Arrhythmias Post-Closure

  • Atrial tachyarrhythmias: Occur in approximately 5.2% of patients within 4 months post-device placement 6

    • Atrial fibrillation (most common)
    • Atrial flutter
    • Increased supraventricular ectopy (63% of patients) 7
  • Conduction abnormalities:

    • Complete heart block: Rare but serious (0.3-0.85% incidence) 8, 6
    • First-degree AV block: New-onset first-degree AV block post-procedure is associated with increased risk of atrial tachyarrhythmias 6
    • Second-degree AV block: Can occur, particularly Type II 7
    • Most conduction abnormalities occur within 3-7 days post-procedure 8

Red Flags on Follow-Up ECG

  • Failure of ECG normalization (persistent right axis deviation, persistent RBBB patterns) should prompt evaluation for:

    • Residual shunt 2
    • Pulmonary complications 2
    • Device malposition
  • Prolonged PQ intervals with minimal shortening post-closure indicate:

    • More advanced clinical condition 9
    • Higher risk of paroxysmal atrial fibrillation and heart failure 9
    • Less structural normalization of right heart 9

Clinical Pitfalls and Caveats

Early Post-Procedure Period (First 6 Months)

  • Paradoxical ECG worsening: P-wave duration may initially increase despite volumetric unloading due to device "foreign body" effect 3
  • This warrants closer ECG monitoring during the first few weeks after device implantation 3
  • Increased supraventricular ectopy is common and usually benign 6, 7

Device-Specific Considerations

  • Device size and patient age are predictive factors for AV block 8
  • Larger devices (mean 16 mm, range 5-38 mm) may have higher arrhythmia risk 6
  • Device erosion can present with chest pain or syncope and warrants urgent evaluation 4, 5, 4

Long-Term Monitoring Considerations

  • Patients with prolonged PQ intervals (≥200 ms) before closure require more intensive follow-up as they have:

    • Higher incidence of paroxysmal atrial fibrillation 9
    • Higher incidence of heart failure 9
    • Less favorable structural remodeling 9
  • Surgical closure patients who had ASD repair in childhood are generally free of late complications and may not require indefinite follow-up 4

When to Escalate Monitoring

Beyond routine ECG, consider Holter monitoring if:

  • New symptoms of palpitations, syncope, or chest pain develop
  • Screening ECG shows new arrhythmias
  • Patient had pre-existing arrhythmias before closure 4, 5, 4

The evidence strongly supports that clinical and ECG surveillance for recurrent or new-onset arrhythmia is an important feature of postoperative evaluation 4, 5, 4, and detailed ECG analysis combined with other clinical parameters helps predict structural normalization and identify patients at higher risk for complications 9.

References

Research

Short-term electrogeometric atrial remodelling after percutaneous atrial septal defect closure.

Journal of cardiovascular medicine (Hagerstown, Md.), 2008

Research

Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closure.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2011

Research

Early ECG abnormalities associated with transcatheter closure of atrial septal defects using the Amplatzer septal occluder.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2000

Related Questions

Which of the following statements about atrial septal defect is false?
In a 57‑year‑old diabetic female with a newly diagnosed ostium secundum atrial septal defect causing a left‑to‑right shunt and dilated right atrium and right ventricle, what clinical findings should be expected?
How should a 20-year-old female with a history of atrial septal defect (ASD) closure eight years ago who now presents with severe abdominal distension and occasional pedal edema be managed?
What is the recommended management for a patient with a Doppler finding consistent with a moderate-sized ostium secundum atrial septal defect?
What is the appropriate management for a patient with an atrial septal defect (ASD) who also has a prolonged QT interval?
How should renal pain that begins after a rapid intravenous fluid bolus be evaluated and managed?
What are the Joint National Committee 7 (JNC 7) criteria for classifying blood pressure and their associated management recommendations?
What is the appropriate deep vein thrombosis prophylaxis regimen for a hospitalized patient?
Is there clinical evidence that Chinese herbal formulas, Turkey Tail mushroom (Coriolus versicolor), or the mushroom extract AHCC improve tumor response or overall survival in cancer patients, and what specific interactions do they have with chemotherapy or immunotherapy?
Can vaping cause polycythemia (elevated hematocrit) similar to that seen in traditional cigarette smokers?
In a morbidly obese patient with BMI approximately 42 kg/m², how accurate is the Eleveld target‑controlled infusion (TCI) model for propofol compared with the Marsh and Schnider models?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.